New insights into autoantibodies could improve diagnosis and management in PBC
According to a research review, broader autoantibody study could help with more accurate PBC diagnosis and lead to more personalized care.
According to a research review, broader autoantibody study could help with more accurate PBC diagnosis and lead to more personalized care.
PPAR agonists reduced biomarkers of liver dysfunction compared to placebo across several clinical trials of patients with PBC.
Severe pruritus can leave a highly negative impact on patient mental and emotional well-being over time.
Alkaline phosphatase may not be the only liver biomarker that predicts the risk of negative outcomes in patients with PBC, a study found.
Patients with primary biliary cholangitis and related autoimmune liver diseases showed higher PCSK9 levels than healthy people.
Smoking cigarettes is not only linked to a higher risk of PBC, but more severe disease and worse outcomes in those living with it.
Losing tiny bile ducts in the liver (ductopenia) could be a strong warning sign of worse outcomes in people with PBC.
People with primary biliary cholangitis (PBC) who do not receive treatment face much higher medical costs than those who are treated.
Genetic analyses indicate that PBC directly increases the risk of lacunar stroke, suggesting a causal relationship.
Compared to healthy controls, patients with early-stage PBC have altered expression of a class of molecules known as sphingolipids.